<https://rdf.molmedb.upol.cz/reference/ref1916> <http://purl.org/ontology/bibo/pmid> "28287723"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acs.jmedchem.6b01851"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/bibliographicCitation> "Weiss MM, Dineen TA, Marx IE, Altmann S, Boezio A, Bregman H, Chu-Moyer M, DiMauro EF, Feric Bojic E, Foti RS, Gao H, Graceffa R, Gunaydin H, Guzman-Perez A, Huang H, Huang L, Jarosh M, Kornecook T, Kreiman CR, Ligutti J, La DS, Lin MJ, Liu D, Moyer BD, Nguyen HN, Peterson EA, Rose PE, Taborn K, Youngblood BD, Yu V, Fremeau RT.: Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities. J Med Chem, Volume 60 (14), 2017"^^<http://www.w3.org/2001/XMLSchema#string> .
